Hematology-Oncology – Page 11

Risk Stratification Models in Blood or Marrow Transplant Recipients for Predicting Cutaneous Malignant Neoplasms

By MedXY 08/16/2026

Blood or marrow transplant recipients face an increased risk of skin cancers. This study develops validated risk models to identify high-risk patients for basal cell carcinoma, squamous cell carcinoma, and melanoma to optimize surveillance strategies.

Hematology-Oncology news Rheumatology

Low-dose Blinatumomab Therapy in Multidrug-Resistant Rheumatoid Arthritis: A Case Series Analysis

By MedXY 08/16/2026

A case series assessing the safety and efficacy of low-dose blinatumomab in 15 patients with multidrug-resistant rheumatoid arthritis showed synovial B-cell depletion, reduced disease activity, and improved response to previously ineffective DMARDs.

Hematology-Oncology news Pathology & Lab Medicine

ELN‑DAVID technical recommendations: NGS-based FLT3‑ITD MRD testing in AML — what clinicians and labs need to know

By MedXY 08/15/2026

The ELN‑DAVID 2026 technical note establishes standards for NGS-based detection of FLT3‑ITD measurable residual disease (MRD) in AML, with lab validation, reporting, timing, and clinical-use recommendations to make FLT3‑ITD MRD testing actionable in routine care.

Hematology-Oncology news

Real-World Incidence, Risk Factors, and Biomarker Validation for SOS/VOD After Allogeneic HSCT in Adults: Insights from the Spanish GETH-TC Registry

By MedXY 08/12/2026

A comprehensive retrospective analysis of 793 adult allo-HSCT cases identifies key clinical risk factors and validates the EASIX score as a predictive biomarker for SOS/VOD, highlighting the syndrome's significant impact on non-relapse mortality.

Clinical Updates Hematology-Oncology news

Lenalidomide and Oral Azacitidine Combined with Radiotherapy in Plasmacytoma: A Pilot Trial and Perspectives

By MedXY 08/12/2026

This review synthesizes evidence on combining lenalidomide and oral azacitidine with radiotherapy for plasmacytoma, highlighting safety, preliminary efficacy, and translational rationale in newly diagnosed and relapsed patients.

Hematology-Oncology news

USP8 as a Therapeutic Target in B Cell Proteostasis and Multiple Myeloma Resistance

By MedXY 08/12/2026

USP8 regulates proteostasis in B cells and multiple myeloma, influencing cellular survival and response to therapy. Targeting USP8 reveals new opportunities for overcoming proteasome inhibitor resistance in multiple myeloma.

Hematology-Oncology news Pediatrics

Early Inflammatory Complications After Pediatric Haploidentical HSCT with Post-Transplant Cyclophosphamide: Clinical Impact and Risk Factors

By MedXY 08/11/2026

This multicenter study identifies peripheral blood stem cell use as a key risk factor for early inflammatory complications post-haploidentical HSCT in children, linking these events to refractory acute and chronic graft-versus-host disease.

Hematology-Oncology news Pathology & Lab Medicine

Decoding the Tumor Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic Insights from CD163 and CD11c Profiling

By MedXY 08/11/2026

This study identifies distinct tumor immune microenvironment subgroups in diffuse large B-cell lymphoma based on CD163 and CD11c expression, revealing prognostic significance and potential therapeutic stratification with checkpoint inhibitors.

Hematology-Oncology Internal Medicine news

Unraveling the FOLR2-IRF2BP2 Axis: How Excess Folic Acid Impairs Erythropoiesis in Myelodysplastic Neoplasms

By MedXY 08/11/2026

Excess folic acid promotes erythropoiesis impairment in myelodysplastic neoplasms via the FOLR2-IRF2BP2 axis, revealing potential therapeutic targets involving dietary folic acid restriction and pathway inhibition.

Cardiology Hematology-Oncology news

Abelacimab in Atrial Fibrillation: Impact of Prior Anticoagulation Experience on Bleeding Risk

By MedXY 08/11/2026

The AZALEA-TIMI 71 study demonstrates that factor XI inhibition with abelacimab reduces bleeding risk in atrial fibrillation patients regardless of prior oral anticoagulation experience, with a potentially greater absolute benefit in anticoagulation-naïve individuals.

Hematology-Oncology news

Comparing Total Body Irradiation and Chemotherapy Conditioning in Haploidentical Transplants for AML Patients in First Remission: Insights from the EBMT Registry

By MedXY 08/10/2026

This study evaluates survival and relapse outcomes of total body irradiation versus chemotherapy conditioning regimens in haploidentical hematopoietic cell transplantation for adult AML patients in first remission, revealing no clear survival advantage with TBI.

Hematology-Oncology news Oncology

Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial

By MedXY 08/10/2026

The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcomes for a challenging disease.

Hematology-Oncology news

Unveiling Atelis Syndrome: SLF2 and SMC5 Dysfunction as Drivers of Hematopoietic Stem Cell Aging and Myelodysplastic Syndrome Predisposition

By MedXY 08/10/2026

Dysfunction in SLF2 and SMC5 causes premature hematopoietic stem cell aging, bone marrow failure, and early-onset myelodysplastic syndrome in Atelis Syndrome, defining a novel inherited bone marrow failure disorder.

Hematology-Oncology Nephrology news

Renin-Angiotensin-Aldosterone System Inhibitors Worsen Anemia in Sickle Cell Disease: Clinical and Mechanistic Insights

By MedXY 08/10/2026

RAAS inhibitors, used for kidney protection in sickle cell disease, may significantly exacerbate anemia by impairing erythropoiesis, warranting close hemoglobin monitoring in this vulnerable population.

Hematology-Oncology news

Advancing Diagnosis in Myeloproliferative Neoplasms: Non-invasive Multiparametric Profiling of ET, Premyeloﬁbrosis, and Overt Myeloﬁbrosis

By MedXY 08/07/2026

This study evaluates non-invasive biomarkers to differentiate essential thrombocythemia, premyelofibrosis, and overt myelofibrosis, revealing distinct inflammatory and immune profiles and supporting a disease continuum model.

Hematology-Oncology Internal Medicine news

Unveiling BPNT1 Mutations as a Novel Cause of Vitamin B12-Dependent Megaloblastic Anemia

By MedXY 08/07/2026

Biallelic loss-of-function mutations in BPNT1 are identified as a new genetic cause of vitamin B12-dependent megaloblastic anemia, linked to disrupted ribosome biogenesis and impaired ileal vitamin B12 absorption in mouse models.

Cardiology Hematology-Oncology news

Extracranial Bleeding Risk on Oral Anticoagulants in Atrial Fibrillation: Insights from COMBINE-AF Analysis

By MedXY 08/05/2026

This study evaluates the incidence, severity, and predictors of extracranial bleeding in atrial fibrillation patients on oral anticoagulants, highlighting its substantial burden beyond major bleeds and informing bleeding risk management.

Hematology-Oncology Internal Medicine news

Optimizing Outcomes in POEMS Syndrome: Real-World Insights on Autologous Stem Cell Transplantation from a Multicenter Study

By MedXY 08/05/2026

This multicenter study evaluates autologous stem cell transplantation (ASCT) in POEMS syndrome, showing significant hematologic response, durable survival, and manageable toxicity, highlighting ASCT's pivotal role in treatment.

Hematology-Oncology news Oncology

Revolutionizing Classical Hodgkin Lymphoma Treatment: The Promise of Anti-PD-1 Therapy

By MedXY 08/05/2026

Anti-PD-1 therapy has transformed classical Hodgkin lymphoma management, demonstrating safety, feasibility, and durable efficacy across treatment settings—from relapsed/refractory disease to frontline therapy.

Hematology-Oncology news Oncology

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Insights into Cellular Diversity, Immune Suppression, and Therapeutic Opportunities

By MedXY 08/05/2026

BIA-ALCL is a heterogeneous T cell lymphoma marked by immunosuppressive tumor microenvironments that promote tumor survival and proliferation, revealing potential targets for advanced disease therapy.